PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Roche Holding AG is weighing direct-to-patient drug sales in the US, bypassing the middleman for its pricey medicines for ...

You can buy shares of Healthpeak Properties and Pfizer with well less than $100 at the moment. At the moment, anyone with ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Founded in 1998, Genmab develops customised antibodies for use in cancer treatments. Historically, the group has licensed its technology and the commercialisation of its drugs to large pharma giants ...

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.